Showing 6121-6130 of 9331 results for "".
- Study: Smiling May Not Make Us Appear Younger After Allhttps://practicaldermatology.com/news/study-smiling-may-not-make-us-appear-younger-after-all/2458186/Conventional wisdom suggests that smiling makes you appear younger, but researchers at Ben-Gurion University of the Negev in Israel beg to differ. People who smile are actually perceived as older than those with a deadpan or surprised expression, according
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to
- RCM Imaging of Skin Granted Reimbursement Codes by CMS; Wider Adoption Likelyhttps://practicaldermatology.com/news/rcm-imaging-of-skin-granted-reimbursement-codes-by-cms/2458187/After more than two decades of effort, reflectance confocal microscopy (RCM) imaging of skin has been granted reimbursement codes by the US Centers for Medicare and Medicaid Services. A report in Lasers in Sur
- Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritishttps://practicaldermatology.com/news/pfizer-announces-us-fda-filing-acceptance-of-supplemental-new-drug-application-for-xeljanz-tofacitinib-citrate-for-the-treatment-of-adult-patients-wit/2458195/(via BusinessWire) Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for rev
- Alastin to Present Study Results Demonstrating Anti-aging and Procedure Enhancement Results of TriHex Technologyhttps://practicaldermatology.com/news/alastin-to-present-study-results-demonstrating-effectiveness-of-trihex-technology-for-post-laser-treatment-care/2458197/Alastin Skincare, Inc. will present data on three new studies at the 7th Annual Summit in Aesthetic Medicine meeting in Newport Beach, CA (May 5-7, 2017). "As part of our commitment to generate scientific data related to our Alastin Skincare products and technology, we have been work
- LEO Pharma U.S. Welcomes Judit H. Nyirady as Vice President of Medical Strategy & Scientific Affairshttps://practicaldermatology.com/news/leo-pharma-us-welcomes-judit-h-nyirady-as-vice-president-of-medical-strategy-scientific-affairs/2458194/Judit H. Nyirady, MD, MBA, is the new Vice President of Medical Strategy & Scientific Affairs at LEO Pharma Inc. In this role, she will be responsible for the medical and scientific affairs strategies for LEO Pharma in the United States, as well
- BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acnehttps://practicaldermatology.com/news/biopharmx-reports-positive-topline-results-of-bpx-01-topical-minocycline-for-acne/2458198/BioPharmX Corporation’s topical minocycline for acne, BPX-01, achieved its primary endpoint in a phase 2b clinical trial. There were statistically significant reductions in non-nodular inflammatory acne lesions when compared to vehicle in both the 1 percent and 2 percent doses of BP
- Nutrition for Healing Introduces MEND Cosmetic to Support Improved Healing & Recovery From Cosmetic Surgeryhttps://practicaldermatology.com/news/nutrition-for-healing-introduces-mend-cosmetic-to-support-improved-healing-recovery-from-cosmetic-surgery/2458201/Nutrition For Healing LLC launched its new MEND Cosmetic, which is now available through cosmetic surgeons worldwide. The all natural formula, a blend of clinically researched, proven ingredients designed specifically to support healing from cosmetic surgery,
- Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosahttps://practicaldermatology.com/news/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa/2458202/Abeona Therapeutics, Inc. has announced updated clinical data from the ongoing Phase 1/2 clinical trial for the EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe fo
- Foamix Announces Additional Phase 3 Trial for FMX101 in Moderate to Severe Acnehttps://practicaldermatology.com/news/foamix-announces-additional-phase-3-trial-for-fmx101-in-moderate-to-severe-acne/2458203/Foamix Pharmaceuticals is launching an additional Phase 3 trial for FMX101 in moderate to severe acne, a topical minocycline treatment. If the results are positive, this new Phase 3 trial is expected to form the basis for a New Drug Application (NDA) which the company plans to submit in t